Generic Name and Formulations:
Carbidopa, levodopa; 23.75mg/95mg, 36.25mg/145mg, 48.75mg/195mg, 61.25mg/245mg; ext-rel caps.
Impax Laboratories, Inc.
Indications for RYTARY:
Treatment of Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication.
Swallow whole. If difficulty swallowing, may open capsule and sprinkle contents on applesauce (1–2tbsp); consume immediately. Individualize. Levodopa-naive: initially 23.75mg/95mg 3 times daily for the first 3 days; may increase to 36.25mg/145mg 3 times daily on the fourth day; up to max 97.5mg/390mg 3 times daily. May increase to max 5 times daily if more frequent dosing needed and tolerated. Max daily dose: 612.5mg/2450mg. Converting from IR carbidopa-levodopa: see full labeling. Currently taking carbidopa-levodopa with concomitant COMT inhibitors (eg, entacapone): may need to increase initial daily dose; see full labeling.
During or within 2 weeks of nonselective MAOIs (eg, phenelzine, tranylcypromine).
Not interchangeable with other carbidopa-levodopa products. Sleep disorders: consider discontinuing if significant daytime sleepiness occurs. History of MI or arrhythmias; monitor cardiac function. Increased risk of hallucinations and psychosis. Major psychotic disorder: not recommended. Impulse control disorders: consider reducing dose or discontinuing if occurs. Peptic ulcer. Glaucoma: monitor intraocular pressure. Perform skin exams to monitor for melanoma. Withdrawal-emergent hyperpyrexia or confusion: avoid sudden discontinuation or rapid dose reduction. Pregnancy (Cat.C). Nursing mothers.
See Contraindications. Orthostatic hypotension with MAO-B inhibitors (eg, rasagiline, selegiline); monitor. Antagonized by dopamine D2 receptor antagonists (eg, phenothiazines, butyrophenones, risperidone, metoclopramide), isoniazid, iron salts. Delayed absorption with high-fat, high-calorie meals.
Dopa-decarboxylase inhibitor + dopamine precursor.
Nausea, dizziness, headache, insomnia, abnormal dreams, dry mouth, dyskinesia (reduce doses), anxiety, constipation, vomiting, orthostatic hypotension.
Ext-rel caps—100, 240
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Adjunctive Therapies for Bipolar Disorder Show Promise, Need More Evidence
- Improving Performance of Everyday Activities Is Critical in Schizophrenia
- Analysis Finds Lithium Maintenance Most Effective as Monotherapy in Bipolar Disorder
- Web-Based Intervention Targets Parental Behaviors That May Affect Adolescent Anxiety, Depression
- Abnormalities of Cortical Thickness in Bipolar Disorder With Auditory Hallucinations
- The Way to the Head May Be Through the Gut: Probiotics for Depression
- Suicide-Screening Toolkit Can Help Identify Youths at High Risk for Suicide
- Agoraphobia: An Evolving Understanding of Definitions and Treatment
- Parental Pressure to Diet Linked With Long-term Harm in Adolescents
- Does Access to Medical Cannabis Reduce Risk for Opioid Abuse?
- Antidepressants Increase Seizure Risk in Youth and Severely Depressed
- Examining Associations Between Diabetes and Effects on Cognition
- Untreated Depression Common in Women of Childbearing Age
- Incidence of Psychiatric Disorders in Rheumatoid Arthritis
- Effect of Antidepressant Class, Dose on Pediatric Anxiety Disorders